さまよう薬剤師のブログ

学位あっても、センスない、現実逃避したい感染すき薬剤師。I have Ph.D. but less sense a ID pharmacist (ICPS). Another face is an investor.

Rates, Predictors and Mortality of Community-Onset Bloodstream Infections due to Pseudomonas aeruginosa: Systematic Review and Meta-Analysis.

CMIに報告された、CO-BSIのメタアナ

www.sciencedirect.com

 

f:id:akinohanayuki:20190421073724j:plain

続きを読む

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus

皮膚・軟部組織感染に対する

Ceftaroline vs VCM

RCT

 

primary outcome 

Early Clinical Response [ Time Frame: 48 to 72 hours after initiation of study drug ]

Reduction of lesion size from baseline of at least 20%

 

Ceftaroline

600 mg IV (over 1 hour) every 12 hours for renal function > 50 mL/min, adjusted for renal function based on package insert for no more than 14 days.
 
Vancomycin
Dosed by institutional pharmacy protocol to reach goal trough level of 10 - 20 mg/L steady state concentration for no more than 14 days.

 

link.springer.com

 

f:id:akinohanayuki:20190421070226j:plain

 

続きを読む

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

NEJMに報告された、リファンピン耐性結核に対するより短期のレジメンのRCT : STREAM

非劣勢 P3。

  • フルオロキノロン系とアミノグリコシド系に感受性を示すリファンピン耐性結核患者を対象
  • 高用量のモキシフロキサシンを含む短期レジメン(9~11 ヵ月)を受ける群
  • The short regimen consisted of moxifloxacin (high-dose), clofazimine, ethambutol, and pyrazinamide administered over a 40-week period, supplemented by kanamycin, isoniazid, and prothionamide in the first 16 weeks
  • 2011 年の WHO ガイドラインに従った長期レジメン(20 ヵ月)を受ける群
  • 主要有効性転帰は 132 週の時点での良好な状態とし,結核菌(Mycobacterium tuberculosis)の培養が 132 週とその前の時点で陰性で,その間に陽性はなく,それ以前に不良な転帰もないことと
  • 非劣性は,10 パーセントポイント以下

 

https://www.nejm.org/doi/full/10.1056/NEJMoa1811867

clinicaltrials.gov

f:id:akinohanayuki:20190407072903j:plain

続きを読む